{"entity":{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","aka":["Foresee Pharmaceuticals Co., Ltd.","Foresee"],"tldr":"Foresee is a Taipei biotech whose long-acting leuprolide depot, Camcevi, is an injection for advanced prostate cancer, and which runs phase 3 trials as lead sponsor.","summary":"Foresee Pharmaceuticals, headquartered in Taipei, Taiwan, developed a ready-to-use six-month leuprolide mesylate depot (Camcevi) for advanced prostate cancer, approved in the United States and Europe, and is developing further hormone and immunology products. It is lead sponsor of several phase 3 trials registered on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.foreseepharma.com"},{"label":"ClinicalTrials.gov: trials led by Foresee Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Foresee%20Pharmaceuticals"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045369"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["leuprolide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.foreseepharma.com","stage":"public","investors":[],"funding":[]},"route":"/companies/foresee-pharmaceuticals/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/"}]}}